Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + prednisolone
- Development stage
- Discontinued
- Lead developer
- CombinatoRx
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
CRx-139 is an oral synergistic combination drug candidate composed of low-dose prednisolone (a glucocorticoid steroid) and paroxetine (a selective serotonin reuptake inhibitor antidepressant). It was developed to enhance the immuno-modulatory activity of a low-dose glucocorticoid while minimizing steroid-related side effects. The combination targets multiple biological pathways simultaneously and is designed for the treatment of immuno-inflammatory diseases, particularly rheumatoid arthritis. Mechanistically, CRx-139 inhibits pro-inflammatory biomarkers such as TNF-alpha, IL-6, and C-reactive protein while increasing anti-inflammatory cytokine IL-10. The drug was developed by CombinatoRx as part of their approach to create novel synergistic pharmaceuticals that act on complex disease biology[1][2][3][4][5].
- Other names
- paroxetine + prednisoloneCRx-139CRx139CRx 139
02
Targets
IL10 (Interleukin-10)SERT (Sodium-dependent serotonin transporter)TNFA (Tumor necrosis factor alpha (soluble))GR (Glucocorticoid receptor)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on paroxetine + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + prednisolone.